Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Sponsored
Interactive Tools
Learning Modules
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Sharyn N. Lewin, MD, Holy Name Medical Center
home
Articles
Systemic Management of Ovarian Cancer: Closing Thoughts
May 27th 2020
Novel Combination Strategies in Recurrent Ovarian Cancer
May 27th 2020
Recurrent Ovarian Cancer: Novel Agents Under Investigation
May 27th 2020
Bevacizumab’s Role in Recurrent Ovarian Cancer
May 27th 2020
Recurrent Ovarian Cancer: Choosing a PARP Inhibitor
May 27th 2020
PARP Inhibition’s Role in Recurrent Ovarian Cancer
May 27th 2020
Frontline Ovarian Cancer Management: Ongoing Clinical Trials
May 27th 2020
Considerations for the JAVELIN OVARIAN 100 Study
May 27th 2020
Ovarian Cancer: Maintenance Following Frontline Bevacizumab
May 27th 2020
Ovarian Cancer: Updates to NCCN Guidelines
May 27th 2020
Treating Ovarian Cancer Based on HRD Status
May 27th 2020
Ovarian Cancer: What is the Role of HRD Testing?
May 27th 2020
Ovarian Cancer: Factors in Deciding on Maintenance Therapy
May 27th 2020
PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer
May 27th 2020
Practical Applications of PRIMA in Ovarian Cancer Management
May 27th 2020
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
May 27th 2020
SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer
May 27th 2020
GOG-0218: Frontline Bevacizumab in Ovarian Cancer
May 27th 2020